Initial Glasgow Coma Scale score predicts outcome following thrombolysis for posterior circulation stroke.
暂无分享,去创建一个
Wade S. Smith | J. Tsao | J. Hemphill | S. Johnston | D. Bonovich | Jack W Tsao | Wade S Smith | J Claude Hemphill | S Claiborne Johnston | David C Bonovich
[1] L. Pazdera,et al. Outcome at 30 days in the New England Medical Center Posterior Circulation Registry. , 2002, Archives of neurology.
[2] M. Hommel,et al. Thrombolytic therapy with streptokinase in acute ischemic stroke. , 1996, The New England journal of medicine.
[3] S. Felber,et al. Long-Term Outcome after Local Intra-Arterial Fibrinolysis of Basilar Artery Thrombosis , 2000, Cerebrovascular Diseases.
[4] G. Schroth,et al. Local intra-arterial thrombolysis in acute ischemic stroke. , 1998, Stroke.
[5] M. Kaste,et al. The European Cooperative Acute Stroke Study (ECASS) , 1993 .
[6] M. Pessin,et al. Basilar artery occlusive disease in the New England Medical Center Posterior Circulation Registry. , 2004, Archives of neurology.
[7] G. Donnan,et al. Thrombolysis in the Vertebrobasilar Circulation: The Australian Urokinase Stroke Trial , 1997 .
[8] W. Hacke,et al. Thrombolytic therapy of acute basilar artery occlusion. Variables affecting recanalization and outcome. , 1996, Stroke.
[9] Multicentre Acute Stroke Trial—Italy Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke , 1995, The Lancet.
[10] Gregory,et al. Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. , 1988, Stroke.
[11] G. Hankey,et al. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. , 1996, Journal of the American Medical Association (JAMA).
[12] M. Kaste,et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) , 1995, JAMA.
[13] Joseph P. Broderick,et al. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .
[14] M. Kaste,et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) , 1998, The Lancet.
[15] Koroshetz Wj,et al. Tissue plasminogen activator for acute ischemic stroke. , 1996, The New England journal of medicine.
[16] M. Diringer,et al. Relationship between clot location and outcome after basilar artery thrombolysis. , 1997, AJNR. American journal of neuroradiology.
[17] C. Derdeyn,et al. Collateral circulation and outcome after basilar artery thrombolysis. , 1998, AJNR. American journal of neuroradiology.
[18] W. Heiss,et al. Early intravenous thrombolysis with recombinant tissue-type plasminogen activator in vertebrobasilar ischemic stroke. , 1998, Archives of neurology.
[19] G. Schlaug,et al. Diffusion-weighted imaging and National Institutes of Health Stroke Scale in the acute phase of posterior-circulation stroke. , 2001, Archives of neurology.
[20] W. Hacke,et al. Acute vertebral-basilar thrombosis. Angiologic-clinical comparison and therapeutic implications. , 1986, Acta radiologica. Supplementum.
[21] P. Adeleine,et al. Intravenous r-TPA in vertebrobasilar acute infarcts , 2004, Neurology.
[22] E. Dooley. National Institute of Neurological Disorders and Stroke , 2006 .
[23] L. Munari,et al. RANDOMIZED CONTROLLED TRIAL OF STREPTOKINASE, ASPIRIN, AND COMBINATION OF BOTH IN TREATMENT OF ACUTE ISCHEMIC STROKE , 1995 .
[24] R. Higashida,et al. Intra-arterial Prourokinase for Acute Ischemic Stroke: The PROACT II Study: A Randomized Controlled Trial , 1999 .
[25] A R Localio,et al. Reliability and validity of estimating the NIH stroke scale score from medical records. , 1999, Stroke.
[26] H. S. Mueller,et al. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.
[27] G. Albers,et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. , 1999, JAMA.